Indonesian Single Rod Implant: A New Breakthrough | Biomed Grid

Implant as a contraceptive device was begun for the clinical trial in 1968 in Santiago, Chile. The tube contained polydimethylsiloxane (silastic or silicon) which was filled by chlormadinone acetate as synthetic gestagen or progestin. However, the trial was stopped due to toxicity in animal experiments [1]. Several years later, six rods implant containing megestrol acetate was run for clinical trial in Chile, India, and Brazil; unfortunately, it stopped because of ectopic pregnancy as consequence of failure [2]. In 1980, there was a trial to compare six- (Norplant®) and two-rod-implant (Norplant-2®) containing levonogestrel (LNG) and continued by the development of Jadena® marketed in Indonesia which was officially accepted by FDA in 1996 [3,4]. Indonesian implant developed single rod marketed as Indoplant® containing 150 mg LNG and Monoplant® consisting of 160 mg LNG. Monoplant® was estimated for 3 years of effectiveness as contraceptive [5]. Therefore, this article would like to present a novel idea in the advancement of Monoplant® for consideration for publication in American Journal of Biomedical Science & Research.